These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 36543986)
1. New cuts for CRISPR effectors. Burgess DJ Nat Rev Genet; 2023 Feb; 24(2):71. PubMed ID: 36543986 [No Abstract] [Full Text] [Related]
2. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research]. Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746 [TBL] [Abstract][Full Text] [Related]
3. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas Advancement in Molecular Diagnostics and Signal Readout Approaches. Ahmed MZ; Badani P; Reddy R; Mishra G J Mol Diagn; 2021 Nov; 23(11):1433-1442. PubMed ID: 34454111 [TBL] [Abstract][Full Text] [Related]
4. Strategies for Optimization of the Clustered Regularly Interspaced Short Palindromic Repeat-Based Genome Editing System for Enhanced Editing Specificity. Wang YM; Wang HZ; Jian YZ; Luo ZT; Shao HW; Zhang WF Hum Gene Ther; 2022 Apr; 33(7-8):358-370. PubMed ID: 34963339 [TBL] [Abstract][Full Text] [Related]
6. The CRISPR-Cas toolbox and gene editing technologies. Liu G; Lin Q; Jin S; Gao C Mol Cell; 2022 Jan; 82(2):333-347. PubMed ID: 34968414 [TBL] [Abstract][Full Text] [Related]
7. [Application of clustered regularly interspaced short palindromic repeats- associated protein 9 gene editing technology for treatment of HBV infection]. Wang YD; Liang QF; Li ZY; Zhao CY Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):860-864. PubMed ID: 30616324 [TBL] [Abstract][Full Text] [Related]
8. [Research advances on the development and application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein system]. Tan JJ; Peng YZ; Huang GT Zhonghua Shao Shang Za Zhi; 2021 Jul; 37(7):681-687. PubMed ID: 34304411 [TBL] [Abstract][Full Text] [Related]
10. CRISPR-Edited Immune Effectors: The End of the Beginning. Mo F; Heslop HE; Mamonkin M Mol Ther; 2020 Apr; 28(4):995-996. PubMed ID: 32203679 [No Abstract] [Full Text] [Related]
11. CRISPR/Cas System: Recent Advances and Future Prospects for Genome Editing. Manghwar H; Lindsey K; Zhang X; Jin S Trends Plant Sci; 2019 Dec; 24(12):1102-1125. PubMed ID: 31727474 [TBL] [Abstract][Full Text] [Related]
12. Strategies for the CRISPR-Based Therapeutics. Li B; Niu Y; Ji W; Dong Y Trends Pharmacol Sci; 2020 Jan; 41(1):55-65. PubMed ID: 31862124 [TBL] [Abstract][Full Text] [Related]
13. Engineering guide RNA to reduce the off-target effects of CRISPR. Wu J; Yin H J Genet Genomics; 2019 Nov; 46(11):523-529. PubMed ID: 31902584 [TBL] [Abstract][Full Text] [Related]
14. CRISPR-P 2.0: An Improved CRISPR-Cas9 Tool for Genome Editing in Plants. Liu H; Ding Y; Zhou Y; Jin W; Xie K; Chen LL Mol Plant; 2017 Mar; 10(3):530-532. PubMed ID: 28089950 [No Abstract] [Full Text] [Related]
15. CRISPR-Cas9: A European position on genome editing. Hirsch F; Lévy Y; Chneiweiss H Nature; 2017 Jan; 541(7635):30. PubMed ID: 28054606 [No Abstract] [Full Text] [Related]